Kazia Therapeutics Limited announced that Sovargen Co., Ltd. has dosed the first patient in a Phase 1b/2a clinical trial of paxalisib for rare seizure disorders, specifically focal cortical dysplasia type 2 and tuberous sclerosis complex. This milestone triggers a $2 million development payment to Kazia under their exclusive licensing agreement entered into in March 2024. The company is also eligible for up to $17 million in additional milestones plus royalties on net sales. Kazia Therapeutics Limited operates as an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology and restore anti-tumor immunity.
